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ABSTRACT 
The aim of present work Formulation and Evaluation of Tropicamide In-situ Gels loaded Solid Lipid Nanoparticles for Ocular Drug 
Delivery. The surface morphological of SLN was carried out by TEM. The Tropicamide loaded solid lipid nanoparticles was 
measured the average particle size was ranges from 182.1+3.12nm to 390.1±2.10 nm. The zeta potential ranges from -0.17±1.4 mV 
to -3.80±1.5 mV. The entrapment efficiency 66.2 % to 89.2 %. Drug content was ranges from 0.112mg/ml to 0.502 mg/ml. The 
percentage yield ranges from was ranges from 0.112mg/ml to 0.502 mg/ml. The polydispersity index ranged from 1.011±0.15 to 
1.327±0.13. These SLN enriched in Chitosan gels the pH of the formulations range from 6.8 to 6.9. The gelling strength ranged from 
129 sec to 152 sec. The bioadhesive force was ranges from 10.21 ±1.15 dynes/cm2 to 15.23 ± 1.22 dynes/cm2. The viscosity was 
ranges from 2212 ± 1.14 cps to 2420± 1.19 cps. The spreadability coefficient was ranges from 11.2 ± 1.10 gms/sec to 13.3 ± 1.21 
gms/sec. The in-vitro diffusion release studies carried out at 12 hrs TSLNGF19 shows the 79.2 ± 0.32. The ex vivo permeation 
studies for optimized formulation the increased drug permeation and corneal accumulation. In vitro corneal permeation profile of 
tropicamide loaded SLN from the chitosan gels and commercial eye drop solution (Tropicacyl) across the isolated porcine cornea. 
The ocular tolerance studies performed with HETCAM assay, corneal hydration study, histopathological studies. The stability 
studies of chitosan gels for long-term stability as per ICH guidelines (25°C ± 2°C / 60% RH ± 5% RH) &accelerated stability as per 
ICH guidelines (40°C ± 2°C / 75% RH ± 5% RH) there is no changes in gelling strength, bioadhesive force, viscosity, spreadability 
coefficient in optimized formulation. 
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INTRODUCTION 
Ocular drug delivery systems using a nanotechnology 
have the potential to enhance the corneal residence time 
of the drug to reduce the faster clearance of drug from 
the eyes 
1
. So many attempts were performed in the 
history to fix this problem in ocular drug delivery. The 
solid lipid nanoparticles are the most promising method 
for ocular drug delivery 
2
. Nanotechnology has 
properties like smaller size range, enhanced surface area 
and easily suspending in liquids, various optical and 
magnetic properties are offered by nanotechnology than 
conventional drug delivery systems. The residence time 
of drugs in the precorneal area can be enhanced by use 
of mucoadhesive polymers 
3
. Among them, chitosan 
shows several important biological properties, like 
biodegradability, low toxicity, biocompatibility and 
mucoadhesiveness. Chitosan is a deacetylated form of 
chitin, after cellulose it is the second most abundant 
polymer in nature 
6
. Chitin is hydrophobic but in 
contrast, chitosan is soluble in acidic solutions, the ionic 
interaction between positively charged amino group of 
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chitosan and negative charged sialic acid residue in 
mucus lead to mucoadhesion mechanism 
5
. These 
unique properties makes chitosan a versatile biopolymer 
and useful for development of ocular drug delivery 
systems. Tropicamide (BCS Class-II drug) is an 
antimuscarinic agent used to produces mydriasis 
4
. It is 
frequently used during eye examinations for eye 
surgery, funduscopic examination, cycloplegic 
retinoscopy, cycloplegia. It blocks receptor in the 
muscles of the eye and control the size of pupil and lens 
shape. Tropicamide produces mydriasis due to blockage 
of receptors 
4
. It has the fastest (25-45 min.) and briefest 
(4-6 hours) action. It is used as a short-acting mydriatic 
in fundoscopy. The positive or negative charge of the 
hydrophilic polymer was complexes with a multivalent 
cationic or anionic to form viscous gel particles having 
size range of nanometer 
7
. The goal of present work 
SLNs can be an effective ocular drug delivery system by 
enhance the residence time of drug in eye by 
mucoadhesion which can leads to enhance the 
bioavailability and reducing dosing frequency 
9
. 
MATERIALS & METHODS 
The tropicamide was purchased from Optica 
Pharmaceuticals Pvt. Ltd (Yamunanagar, India). lipid 
Glyceryl trimyristate was procured from S.D. Fine 
Chemical Ltd, Mumbai, Dioleyl trimethyl ammonium 
propane was procured from Avanti Polar Lipids, 
Alabaster, Alabama. Polycaprolactone, Glyceryl 
monostearate, chitosan was procured from sigma 
Aldrich Chemical Pvt Limited. Polysorbate 80 acquires 
from Microfine chemicals in Erode, India. All other 
reagents used were of analytical grade. 
METHODOLOGY 
Preparation of solid lipid nanoparticles:  
In this technique, the drug (tropicamide) containing 
lipids in different ratios melt in cooled, solid lipid group 
these lipid nanoparticles are dispersed in cold surfactant 
(polysorbate 80) solution yielding a pre-suspension. 
Homogenizations was carried out at 8000 rpm reduce 
into small particles temperature was maintained at -5
o
C -
10
o
C with the help of a Remi homogenizer for 5 mints 
8
. 
Then this presuspension is homogenized at below room 
temperature the gravitational force is strong enough to 
break the lipid into microparticles directly to SLN. The 
tropicamide loaded SLN were Lyophilised using a 
programmable freeze dryer (FDU-1100; Eyela, Japan). 
Before freezing, cryoprotectants were added to the SLN 
dispersion. Maltose and sucrose were screened at the 
levels of 5% and 10% (w/v) for their cryoprotectant 
ability, while lactose was screened at the levels of 2.5% 
and 5% (w/v). The freeze drying was conducted as 
follows: primary drying of the dispersion was at -35°C 
for 1 h. The shelf temperature was then raised to -25°C 
for 12 h. secondary drying was performed at 15°C for 4 
h. Formulation design is shown in table 1. 
  
Table 1: Formulation Design of solid lipid nanoparticles  
Formulation 
code 
 
Tropicamide 
drug (mg) 
Lipids (gms) 
Glyceryl 
trimyristate 
Dioleyl trimethyl 
ammonium propane  
Polycarpol 
acetone 
Glyceryl 
monostearate 
TSLNF1 1 1 - - - 
TSLNF2 1 1.5 - - - 
TSLNF3 1 2 - - - 
TSLNF4 1 2.5 - - - 
TSLNF5 1 - 1 - - 
TSLNF6 1 - 1.5 - - 
TSLNF7 1 - 2 - - 
TSLNF8 1 - 2.5 - - 
TSLNF9 1 - - 1 - 
TSLNF10 1 - - 1.5 - 
TSLNF11 1 - - 2 - 
TSLNF12 1 - - 2.5 - 
TSLNF13 1 - - - 1 
TSLNF14 1 - - - 1.5 
TSLNF15 1 - - - 2 
TSLNF16 1 - - - 2.5 
TSLNF17 1 1 0.2 - - 
TSLNF18 1 1 0.4 - - 
TSLNF19 1 1 0.6 - - 
TSLNF20 1 1 - 0.2 - 
TSLNF21 1 1 - 0.4 - 
TSLNF22 1 1 - 0.6 - 
TSLNF23 1 1 - - 0.2 
TSLNF24 1 1 - - 0.4 
TSLNF25 1 1 - - 0.6 
Note: 5% of polysorbate 80 was used as a surfactant in all above formulations, 1:1 ratio of chloroform and menthol used as organic solvents in all the 
above formulations. 
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Preparation of solid lipid nanoparticles enriched in 
gels:  
The optimized Tropicamide loaded SLN assimilate in 
prepared gels using chitosan (1%, 1.5%, & 2% w/v), 
Carboxymethylcellulose Sodium (0.5%) used as 
lubricating agent and glycerol (1% v/v) as hydrating 
agent taken in a beaker with continues stirring finally 
add preservatives (Benzalkonium chloride 0.02%) to 
store for a long time 
11
, finally adjust with pH 6.5. 
Compatibility studies of the drug, the lipid, and 
polymers:  
The FTIR spectrum of the pure form of tropicamide, 
physical mixtures are carried out with FTIR 
12
.   
Morphological studies:  
The following methods are used to determine overall 
shape and morphology of solid lipid nanoparticles 
performed with Transmission electron microscopy 
13
. 
Evaluation parameters for Tropicamide Loaded 
Solid Lipid Nanoparticles: 
Particle size analysis:  
The SLN was inflexible by using Malvern particle size 
analyzer. The Polydispersity index (Đ) is a measurement 
of the distribution of molecular mass in a given polymer 
[14]. PDI of a polymer is calculated as follows 
     
  
  
 
              Where,  
Mw is the weight average molecular weight and  
Mn is the number average molecular weight.  
Zeta potential:  
The SLN enriched gels was estimated by zeta analyzer. 
The SLN dispersions and tropicamide SLN were diluted 
up to (1:100) and it was measured at 25
o
C by keeping 
the electric field strength around 23.2 V/cm.  
Entrapment efficiency:  
The prepared SLN dissolved in distilled water was kept 
in centrifuged up to 14,000 rpm for 40 mins at 10
o
C.  
The sample was observed in UV Visible 
spectrophotometer at ƛ max 254 nm.  
                      
                              
                    
      
Drug content:  
Accurately weight 10 mg of the formulation was taken 
and mixed with small quantity of methanol. Then the 
formulation is warmed on the water bath so that the drug 
was easily dissolved in the formulation. Then the 
solution was placed in whatman filter paper 
15
. The 
volumetric flask makes up to the mark by methanol to 
give a concentration of 1000 µg/ml for tropicamide. The 
volumetric flask to give a concentration of 10µg/ml and 
then absorbance was measured at 254 nm.  
Percentage Yield:  
It was calculated to determine whether the drug into the 
polymer was efficient. The raw material, active 
ingredients, when the manufacturing process of 
nanoparticles 
16
. The produced results were determined 
by weighing the nanoparticles and determined the 
percentage result of added materials weight that was the 
weight of drug and polymer which were added. 
                 
                                     
                 
      
 Evaluation of solid lipid nanoparticles Loaded Gels:  
The SLNs were encapsulating with different 
concentration 1%, 1.5% & 2% Chitosan gels. The 
Formulated SLN enriched in Chitosan gel 
characterization as listed below.  
Gelling strength:  
In 100 ml measuring cylinder containing 50 gm of a gel 
at thermostat at 37
o
C, it allows to penetrate into the 
Chitosan gel. At physiological temperature while 
applying pressure on the device sink at 5cm down, to 
measure the time in seconds 
17
.  
Bioadhesive force:  
All the optimized batches as follows, the chicken cheek 
portion of a mucosa was kept in a glass vial. The vial 
connected with mucosa in an inverted position while the 
first vial was placed on a height adjustable pan. Then the 
second vial was placed on mucosal surfaces of both 
vials. Then weight was kept rising in the pan until vials 
get detached. The minimum weight required to detach 
two vials 
18
.  
Viscosity:  
The prepared Gels enriched in SLN were carried out by 
using Brookfield viscometer.   
Spreadability coefficient:  
The gels were placed in between the two glass slides and 
compressed to uniform thickness then kept weight up to 
1000g for 5 min. weight (50 g) was placed on the pan. 
The time in which the upper glass slide moves over to 
the lower plate was taken as a measure of spreadability 
(S). 
S= ML/T 
Where  
M = weight tide to upper slide (g)  
L = length moved on the glass slide (cm)  
T = time taken (sec) 
Visual appearance & pH:  
The pH of tropicamide loaded SLN incorporated gels 
formulations were measured in pH paper. 
In vitro Franz’s diffusion:  
In vitro release studies were performed using standard 
Franz diffusion cells (FDC-6, LOGAN Instrument 
Corp., Somerset, NJ, USA). The diffusion area was 0.75 
cm2 and receptor volume was 5.0 mL.   Receptor 
chambers were filled with 5 ml of PBS (pH 7.4; 
osmolality 297 mosm/kg) and constantly stirred by small 
magnetic bars. The receptor fluid was stirred with a 
magnetic rotor at a speed of 600 rpm and the 
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temperature was maintained at 35 ±0.5°C in order to 
mimic the ocular surface temperature 
19
. Donor and 
receptor chambers were separated by means of activated 
dialysis membrane bag (molecular weight cut off 12,000 
Da). One millilitres of each formulation was loaded into 
the donor compartment before occluding the chamber 
with Para-film. Samples were withdrawn at regular 
intervals (1, 3, 5, 8, and 12h filtered through a 0.45-µm 
membrane filter and analyzed for drug content by UV- 
Visible spectrophotometer method measured at ƛmax 
254nm. 
Mathematical modeling for drug release profile:  
The cumulative amount of tropicamide released from the 
chitosan gels at different time intervals were fitted with 
Zero order, First order, Higuchi model, and Korsemayer-
peppas model. 
Ex vivo permeation studies:  
It was performed by Franz diffusion cell on the excised 
goat eye collected within 30 min after sacrifice collect 
the freshly excised cornea was tied to one side of the 
open tube (donor compartment) in such a way that its 
epithelial surface faced the donor compartment while the 
endothelial part was exposed to Phosphate buffer pH 7.4 
(receptor compartment). Then you can place 
Tropicamide loaded solid lipid nanoparticles chitosan 
gels in donor compartment. The Phosphate buffer was 
stirred at 50 rpm and maintained the temperature at 37± 
0.5 
o
C. Samples (0.5 mL) were withdrawn from the 
receptor cell after 12hrs analyzed by HPLC. The 
Permeation flux was calculated as the ratio of drug 
permeation rate of the corneal tissue and the cross-
sectional area of the tissue 
20
. The amount of drug 
retained within the corneal tissue was determined using 
HPLC after rinsing (with PBS) and homogenizing the 
tissue. 
Animal Ethical Approval:  
All animal experiments were carried out after approval 
of the protocol by the Institutional Animal Ethical Care 
committee (IAEC), Sri venkateswara college of 
pharmacy, RVS Nagar, Tirupathi road, Chittoor, 
Andhrapradesh  (vide letter no. SVCP/IAEC/0172017-
18) and conducted according to the Indian National 
Science Academy (INSA) guidelines for the use and 
care of experimental animals. 
In vitro corneal permeation study:  
The In vitro Corneal permeation studies of tropicamide-
loaded solid lipid nanoparticles enriched in chitosan gels 
were comparatively evaluated with the commercially 
available eye drops (Tropicacyl 1%, (w/v)) using 
isolated porcine eyes cornea as model Fresh whole 
eyeballs were obtained from the local butcher shop 
immediately after slaughtering and transported to the 
laboratory in cold normal saline within an hour. The 
Cornea was carefully excised along with 2-4 mm of 
scleral tissue and finally cleaned and washed till free 
from proteins with cold normal saline. The isolated 
cornea was mounted by clamping between the donor and 
receptor compartments of modified Franz diffusion cell, 
with endothelial side facing the receptor and epithelial 
side facing the donor. The receptor compartment 
contained 11.5 ml of freshly prepared phosphate 
buffered saline (PBS) pH 7.4 maintained at 35 ±0.5
o
C 
under magnetic stirring. Area available for corneal 
permeation was 0.785 cm
2
. The TSLNGF19 (1 ml) was 
placed in the donor compartment over the cornea. An 
aliquot of 1 ml of the sample was withdrawn from 
receptor compartment at fixed time intervals and 
analyzed for the contents of tropicamide. The study was 
conducted using paired corneas, i.e. one cornea of the 
animal was used for the permeation study of Chitosan 
gels and the contralateral cornea was used for 
conventional eye drops of aqueous drug solution 
21
.  
Determination of tropicamide flux and permeability:  
The cumulative amount of tropicamide permeating 
across the porcine cornea was plotted against time and 
slope of the linear portion of the graph was calculated. 
The steady state flux (J, mg/h/cm2) and apparent 
permeability coefficient (K, cm/h) were calculated as 
follows. 
 s  
  
    
 
Where dQ/dt is the linear portion of the slope (mg/h), A 
is the corneal surface area (in this study, 0.785 cm2), and 
C is the initial drug concentration (mg/ml). 
Ocular tolerance studies: 
i) Hen's Egg Test Chorio Allantoic Membrane 
(HETCAM) assay:  
HETCAM assay was developed for toxicity and 
irritation studies as an alternative method to replace the 
Draize test. In this study, fertilized chicken eggs 
(pathogen-free) were incubated at 37 ± 0.5 ºC, 58 ± 2% 
relative humidity in a standard cell culture incubator up 
to 10 days. At the beginning of the test procedure, the 
outside of the eggs was disinfected and a hole was 
drilled through the pointed pole of the shell, 3ml of 
albumin was removed to allow the CAM to develop in 
an accessible way to treatment 
22
. The hole was sealed 
with molten candle wax. On the 10 th  day, the eggs 
were opened at their blunt ends and the gel substances 
(0.3 mL) were applied to the CAM surface before 
reactions were observed within a specific time limit: 0.5 
min (Ist  phase), 2 min (II nd  phase) and 5 min (III rd  
phase)  
ii) Corneal hydration study:  
The corneal hydration study is one of the important 
parameters to assess any damage to corneal tissue 
(epithelium and/or endothelium). At the end of the ex 
vivo study, each cornea was weighed, soaked in 
methanol, and dried overnight at 90 
O
C, and reweighed 
22
. The percent of corneal hydration was calculated from 
the difference in weight. 
iii) Histopathology:  
The evaluation of cornea provides useful descriptive 
information of corneal damage as well as an assessment 
of the extent of the corneal injury. The isolated corneas 
were exposed to test material followed by fixing in an 
appropriate fixative (e.g., 10% neutral buffered 
formalin). The corneal tissues were then dehydrated 
Yerikala Ramesh et al                                                                                      Journal of Drug Delivery & Therapeutics. 2018; 8(2):194-207          
ISSN: 2250-1177                                                                              [198]                                                                            CODEN (USA): JDDTAO 
using alcohol followed by embedding in low melting 
point paraffin. The corneal sections of thickness 5µ were 
cut, placed on clean glass slides and then depart finished 
22
. Later, the sections were stained with hematoxylin-
eosin and examined under an optical microscope for the 
presences of any changes/damage in the corneal tissues. 
Stability studies:  
Stability study was performed as per International 
Conference on Harmonisation guidelines (ICH) Q1A 
(R2) to assess the prepared hydrophilic drug loaded solid 
lipid nanoparticles enriched in chitosan gels for its 
stability and potential to withstand 
atmospheric/environmental changes 
23
. Prepared 
Tropicamide loaded solid lipid nanoparticles enriched in 
chitosan gels was subjected to stability were packed in a 
clear glass vial and stored at a long term condition (25
°
C 
± 2
°
C / 60% RH ± 5% RH) for 12 months and 
accelerated stability condition (40
°
C ± 2
°
C / 75% RH ± 
5% RH for 6 months in stability chamber. The stored 
samples were analyzed mean gelling strength, 
Bioadhesive force, viscosity, spreadability coefficient, 
pH. 
RESULTS & DISCUSSION 
Compatibility studies:  
Physical mixture of samples was characterized by FTIR 
spectral analysis for any physical as well as chemical 
drug characteristics. There was no interference in the 
functional groups as the principal peaks. The FTIR 
spectrum is display in Figure 02 & interpretation was 
display in table 2. 
   
 
Figure 1: FTIR spectrum of Drug, Lipids, Excipients & Mixture of compounds 
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Table 2: FTIR spectrum of the observed and characteristic peak of Drug, Lipids, Excipients & Mixture of 
compounds 
FTIR Spectrum 
IR absorption bands (cm-1) 
Bond Functional group 
Observed peak Characteristic peak 
Tropicamide 
3678.49 3000-3700 O-H stretch Alkenes,aromatic 
3562.90 3000-3700 O-H stretch Alkenes, aromatic 
3220.11 3000-3700 O-H stretch Alkenes, aromatic 
3090.71 3000-3700 O-H stretch Alkenes, aromatic 
Glycerin trimyristate 
3623.09 3000-3700 O-H stretch Alkenes, aromatic 
3410.81 3000-3700 O-H stretch Alkenes, aromatic 
3215.31 3100-3330 N-H stretch Aromatic ring 
Dioleyl trimethyl 
ammonium propane 
3647.52 3000-3700 O-H stretch Alkenes, aromatic 
3473.00 3000-3700 O-H stretch Alkenes, aromatic 
3170.27 3000-3700 O-H stretch Alkenes, aromatic 
3035.53 3000-3700 O-H stretch Alkenes, aromatic 
2967.04 2500-3000 C-H stretch Alkenes, aromatic 
Polycaprolactone 
3647.88 3000-3700 O-H stretch Alkenes, aromatic 
3557.92 3000-3700 O-H stretch Alkenes, aromatic 
3298.14 3000-3700 O-H stretch Alkenes, aromatic 
Glyceryl monostearate 
2928.92 2960-2850 C-H stretch Alkanes 
3679.72 3700-3500 O-H stretch Free OH alcohols 
1091.08 1150-1070 C-O stretch Ethers 
1297.40 1300-800 C-C stretch Alkenes 
Chitosan 
3359 3000-3700 O-H stretch Free OH alcohols 
2872 2500-3000 C-H stretch Alkenes, aromatic 
1085 1150-1070 C-O stretch Ethers 
1025 1150-1070 C-O stretch Ethers 
Mixture 
3682.31 3000-3700 O-H stretch Alkenes, aromatic 
3154.37 3000-3700 O-H stretch Alkenes, aromatic 
2718.03 2500-3000 C-H stretch Alkenes, aromatic 
2355.95 2100-2660 C=C stretch Alkynes 
 
Morphological characters of Tropicamide Loaded 
SLN:  
The TEM evaluates particle morphology by examining 
the electrons that are transmitted through the specimen. 
An image is produced by interpreting the interaction of 
the electrons passed through the specimen, which is 
visualized by an imaging device or detected by a special 
sensor as shown in figure 2. 
  
    
Figure 2: Tropicamide loaded Solid lipid nanoparticles best formulation TSLNF10 
Characterization of tropicamide loaded solid lipid 
nanoparticles 
Particle size analysis:  
It was analyzed by using Zetasizer Nano-Series. The 
average particle size ranged from 182.1+3.12nm to 
390.1±2.10 nm. All these observations values are 
displayed in Table 3. 
Zeta potential:  
The solid lipid nanoparticles were estimated by Malvern 
zetasizer. The zeta potential ranges from -0.17±1.4 mV 
to -3.80±1.5 mV. All these observations values are 
displayed in Table 3. 
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The entrapment efficiency:  
The solid lipid nanoparticles contain free tropicamide 
ranges from 66.2 % to 89.2 %. All these observations 
values are displayed in Table 3. 
Drug content:  
Tropicamide loaded solid lipid nanoparticles was ranges 
from 0.112mg/ml to 0.502 mg/ml. All these observations 
values are displayed in Table 3. 
Percentage yield: Tropicamide loaded solid lipid 
nanoparticles ranges from 0.8% to 3.8 %. All these 
observations values are displayed in Table 3. 
Polydispersity Index:  
Tropicamide loaded solid lipid nanoparticles was ranges 
from 1.011 ± 0.15 to 1.327 ± 0.13. All these 
observations values are displayed in Table 3. 
 
Table 3: Evaluation parameters of solid lipid nanoparticles 
Formulation 
code 
Particle size* 
(nm) 
Zeta potential* 
(mv) 
Entrapment 
efficiency (%) 
Drug content 
(mg/ml) 
% yield Poly dispersity 
index* 
TSLNF1 182.1+3.12 -0.17±1.4 66.2 0.112 1.8 1.011±0.15 
TSLNF2 191.2±3.19 -0.27±1.6 68.4 0.131 2.4 1.121±0.17 
TSLNF3 201.5±2.18 -0.31±1.8 70.2 0.142 2.9 1.215±0.19 
TSLNF4 213.6±2.10 -0.39±1.9 72.6 0.212 3.4 1.245±0.23 
TSLNF5 190.1±3.23 -1.21±1.2 67.8 0.121 1.9 1.025±0.16 
TSLNF6 210.2±3.40 -1.25±1.3 69.3 0.133 2.3 1.128±0.18 
TSLNF7 227.5±2.17 -1.40±1.5 72.5 0.144 2.8 1.229±0.20 
TSLNF8 235.1±2.13 -2.12±1.7 74.6 0.216 3.4 1.250±0.22 
TSLNF9 192.3±3.81 -0.18±1.6 68.9 0.124 1.9 1.027±0.17 
TSLNF10 212.3±3.91 -0.30±1.9 70.5 0.132 2.3 1.130±0.20 
TSLNF11 240.1±2.12 -0.50±2.0 72.4 0.146 2.9 1.205±0.23 
TSLNF12 310.2±2.09 -1.80±2.2 75.6 0.218 3.4 1.315±0.15 
TSLNF13 194.2±3.61 -0.22±2.0 69.8 0.131 1.9 1.131±0.18 
TSLNF14 240.5±2.15 -0.59±2.3 71.4 0.134 2.4 1.141±0.20 
TSLNF15 267.3±2.16 -0.90±2.7 74.3 0.149 2.8 1.230±0.22 
TSLNF16 340.1±3.12 -1.18±2.9 77.6 0.223 3.4 1.245±0.23 
TSLNF17 211.1±3.12 -2.18±2.1 79.2 0.316 2.0 1.219±0.19 
TSLNF18 250.6±2.19 -2.60±1.8 82.4 0.391 2.2 1.215±0.24 
TSLNF19 301.5±2.15 -3.80±1.5 85.6 0.412 2.5 1.326±0.29 
TSLNF20 212.2±2.15 -2.85±1.6 81.3 0.418 2.1 1.220±0.20 
TSLNF21 251.3±3.21 -2.95±1.8 84.5 0.487 2.3 1.241±0.15 
TSLNF22 351.3±1.67 -3.12±1.5 87.3 0.512 2.4 1.327±0.13 
TSLNF23 210.1±3.18 -2.90±1.6 83.4 0.412 2.1 1.225±0.22 
TSLNF24 261.4±2.15 -3.181.9 86.3 0.451 2.2 1.245±0.13 
TSLNF25 390.1±2.10 -3.20±2.0 89.2 0.502 2.5 1.326±0.19 
                *Values are mean of triplicate ± SD 
 
Evaluation of solid lipid nanoparticles loaded 
Chitosan Gels:  
The tropicamide SLNs were incorporated in different 
concentration 1%, 1.5%, 2 % of Chitosan gels. From the 
above 25 formulation selected formulations chosen the 
Chitosan gel TSLNGF3, 4, 7, 8, 11, 12, 15, 16, 17, 18, 
19, 21, 22, 24, & 25 characterization as displayed below.  
Visual appearance and pH:  
All the formulations were found to be transparent white 
color and in semi-solid consistency. The pH of the 
formulations ranges from 6.8 to 6.9.  
Gelling strength:  
The gelling strength of solid lipid nanoparticles loaded 
gels range from 129 sec to 152 sec. All these 
observations values are displayed in Table 4. 
Bioadhesive force:  
The Bioadhesive force of all formulations ranged from 
10.21 ±1.15 dynes/cm
2 
to 15.23 ± 1.22 dynes/cm
2
. All 
these observations are displayed in Table 4. 
Viscosity:  
The rheological studies of all formulations were ranges 
from 2212 ± 1.14 cps to 2420± 1.19 cps. All the values 
are displayed in Table 4. 
Spreadability coefficient:  
all the formulation ranged from 11.2 ± 1.10 gms/sec to 
13.3 ± 1.21 gms/sec. All these observations are listed in 
Table 4. 
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Table 4: Evaluation parameters of Solid lipid nanoparticles loaded chitosan gels 
Formulation 
code 
Gelling properties 
Gelling 
strength (sec) 
Bioadhesive 
force* 
(dynes/cm
2
) 
Viscosity* 
(cp) 
Spreadiability 
Coefficient* 
(gm/sec) 
pH 
TSLNGF3      129 10.21±1.15 2212±1.14 11.2±1.10 6.9 
TSLNGF4    139 11.21±1.17 2321±1.10 11.5±1.13 6.9 
TSLNGF7      141 12.49±1.20 2352±1.18 12.0±1.16 6.9 
TSLNGF8      131 13.19±1.24 2215±1.16 11.5±1.12 6.9 
TSLNGF11   142 9.21±1.03 2325±1.10 11.9±1.15 6.8 
TSLNGF12   144 10.18±1.21 2349±1.20 12.1±1.18 6.8 
TSLNGF15    133 10.29±1.42 2216±1.21 10.5±1.15 6.9 
TSLNGF16  145 11.16±1.53 2330±1.24 12.2±1.14 6.8 
TSLNGF17    146 13.41±1.18 2418±1.20 12.5±1.20 6.8 
TSLNGF18   135 14.01±1.20 2420±1.19 12.4±1.19 6.9 
TSLNGF19  148 15.23±1.22 2519±1.15 13.3±1.21 6.9 
TSLNGF21   150 11.21±1.42 2418±1.10 12.9±1.23 6.8 
TSLNGF22   139 12.18±1.51 2412±1.16 12.6±1.22 6.9 
TSLNGF24  150 11.89±1.35 2398±1.24 13.0±1.25 6.9 
TSLNGF25     152 12.15±1.21 2410±1.20 13.2±1.26 6.9 
                            *Values are mean of triplicate ± SD 
In-vitro diffusion release studies:  
The drug release studies were performed in a phosphate 
buffer of pH 7.4 suspending the formulation with the 
5mg equivalent of the drug. For all formulations 
respectively, in a span of 12hrs of study. The optimized 
formulations were subjected in the data analysis. The all 
formulations were subjected to data analysis and it was 
found to be first order drug release. The values are 
displayed in Table 5 & 6 Figures 3. 
 
Table 5: in Vitro Franz’s diffusion studies of Chitosan Gels enriched in Tropicamide loaded Solid Lipid 
Nanoparticles  
Time 
(hrs) 
Cumulative Percent drug release after each time interval* 
TSLNGF3  TSLNGF4  TSLN
GF7  
TSLN
GF8  
TSLN
GF11  
TSLN
GF12  
TSLN
GF15  
TSLN
GF16  
TSLN
GF17  
1 5.1 ± 0.61 6.5±0.92 8.3 ± 
0.82 
9.3 ± 
0.51 
8.3 ± 
0.12 
9.4 ± 
0.22 
10.2 ± 
0.27 
09.2 ± 
0.15 
06.3 ± 
0.17 
2 11.3±1.11 14.2± 0.86 16.1 ± 
0.62 
13.2 ± 
1.46 
12.1 ± 
0.41 
13.3 ± 
0.15 
15.1 ± 
1.62 
13.5 ± 
0.24 
13.3 ± 
0.42 
3 12.4 ±1.52 19.2±0.63 23.3 ± 
0.82 
19.4 ± 
0.22 
19.3 ± 
0.53 
25.3 ± 
0.23 
21.5 ± 
0.36 
24.2 ± 
0.26 
19.2 ± 
1.63 
4 19.3 ±2.21 29.2±1.2 29.1 ± 
1.32 
24.5 ± 
0.62 
25.4 ± 
0.15 
34.2 ± 
0.43 
33.2 ± 
0.48 
31.2 ± 
0.53 
23.8 ± 
0.54 
5 24.5±1.41 34.7±1.6 36.2 ± 
1.33 
29.3 ± 
0.31 
33.1 ± 
0.53 
39.1 ± 
0.41 
39.5 ± 
0.52 
39.2 ± 
0.53 
29.4 ± 
0.53 
6 34.7±1.31 40.2±1.54 41.2 ± 
1.63 
35.1 ± 
0.52 
39.7 ± 
0.62 
42.2 ± 
0.22 
42.5 ± 
0.62 
43.4 ± 
1.63 
38.2 ± 
0.63 
7 41.8±1.61 47.4±1.32 48.5 ± 
1.57 
39.1 ± 
1.23 
43.1 ± 
0.25 
49.2 ± 
0.42 
48.3 ± 
0.32 
52.4 ± 
1.32 
42.4 ± 
0.34  
8 49.7± 3.21 52.5±1.34 53.8 ± 
1.63 
 46.5 ± 
1.41 
49.3 ± 
0.28 
53.2 ± 
0.48 
52.2 ± 
1.46 
59.4 ± 
1.42 
53.3 ± 
1.32 
9 53.6 ±2.42 58.6± 2.13  61.7 ± 
1.73 
 52.4 ± 
1.52 
54.3 ± 
0.53 
61.3 ± 
1.86 
58.4 ± 
1.82 
65.3 ± 
0.34 
60.4 ± 
1.34 
10 59.4 ±2.61 64.8± 1.54  62.8 ± 
1.53 
59.2 ± 
1.23 
60.5 ± 
0.52 
68.3 ± 
1.56 
67.6 ± 
1.73 
63.3 ± 
0.43 
68.3 
±1.53 
11 63.7±1.31 67.1± 1.63  68.4 ± 
2.54 
62.2 ± 
0.12 
65.2 ± 
0.15 
70.3 ± 
1.35 
71.3 ± 
1.47 
71.3 ± 
1.24 
73.5 ± 
2.42 
12 67.9 ±2.40 68.5  ± 1.55 70.4 ± 
1.11 
65.3 ± 
2.01 
69.3 ± 
1.51 
72.64 ± 
1.78 
75.27 ± 
2.51 
76.51 ± 
1.21 
78.31 
±1.21 
             *Values are mean of triplicate ± SD 
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Table 6: In Vitro Franz’s diffusion studies of Chitosan Gels enriched inTropicamide loaded Solid lipid 
Nanoparticles  
Time 
(hrs) 
Cumulative Percent drug release after each time interval* 
TSLNGF18 TSLNGF19 TSLNGF21 TSLNGF22 TSLNGF24 TSLNGF25 
1 07.5 ± 0.27 05.2 ± 0.76 08.4 ± 0.26 08.7 ± 1.08 03.6 ± 1.27 08.3 ± 0.36 
2 15.6 ± 0.35 19.6 ± 0.45 19.4 ± 0.33 15.5 ± 0.56 13.7 ± 0.14 16.6 ± 0.56 
3 20.6 ± 0.43 24.3 ± 1.53 24.6 ± 0.53 21.6 ± 0.27 19.7 ± 0.25 23.7 ± 0.65 
4 28.2 ± 0.53 35.6 ± 1.73 31.5 ± 0.43 28.5 ± 0.53 28.7 ± 0.59 29.7 ± 0.32 
5 32.4 ± 0.53 40.4 ± 1.23 40.7 ± 0.63 37.5 ± 0.45 33.8 ± 0.37 34.7 ± 1.72 
6 36.2 ± 0.46 49.3 ± 0.93 48.6 ± 0.23 41.6 ± 0.35 39.6 ± 0.64 39.7 ± 1.63 
7 42.5 ± 1.32 54.2 ± 1.23 53.5 ± 1.34 49.5 ± 0.45 48.3 ± 1.64 42.7 ± 1.87 
8 48.3 ± 1.54 59.5 ± 1.35 59.6 ± 1.53 52.6 ± 0.53 51.6 ± 2.74 49.6 ± 0.63 
9 52.3± 0.34 63.7 ± 1.45 61.7 ± 0.53 60.3 ± 0.72 59.6 ± 1.74 54.7 ± 1.63 
10 62.3 ± 1.34 71.3 ± 0.36 68.4 ± 0.47 67.8 ± 1.52 63.7 ± 0.64 63.8 ± 1.25 
11 72.4 ± 2.45 75.4 ± 2.65 72.5 ± 0.53 72.7 ± 0.63 69.4 ± 1.63 72.7 ± 0.36 
12 78.3 ± 1.22 79.2 ± 0..32 75.4 ± 2.14 76.2 ± 1.21 74.1 ± 2.65 77.1 ± 0.42 
       *Values are mean of triplicate ± SD 
 
 
Figure 3: In Vitro Franz’s diffusion studies of Chitosan Gels enriched inTropicamide loaded Solid lipid 
Nanoparticles  
 
Table 7: Drug Release Kinetics of Chitosan Gels loaded in Solid lipid Nanoparticles Formulations 
Order of Process Formulation code 
TSLNG 
F3 
TSLN
GF4 
TSLNG
F7 
TSLNG
F8 
TSLNG
F11 
TSLNG
F12 
TSLNG
F15 
TSLNG
F16 
Zero order R
2
 0.961 0.967 0.963 0.968 0.921 0.967 0.924 0.932 
First order R
2
 0.974 0.979 0.975 0.973 0.965 0.961 0.967 0.964 
Higuchi R
2
 0.984 0.981 0.984 0.987 0.986 0.983 0.982 0.984 
Hixon R
2
 0.853 0.880 0.980 0.927 0.879 0.922 0.845 0.861 
Korsmeyer R
2
 
n 
0.853 0.952 0.840 0.918 0.873 0.835 0.912 0.961 
0.758 0.755 0.835 0.758 0.792 0.737 0.732 0.774 
Mechanism Non-
Fickian 
Non-
Fickian 
Non-
Fickian 
Non-
Fickian 
Non-
Fickian 
Non-
Fickian 
Non-
Fickian 
Non-
Fickian 
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Table 8: Drug Release Kinetics of Chitosan Gels loaded in Solid lipid Nanoparticles Formulations 
Order of 
Process 
Formulation code 
TSLNGF17 TSLNGF18 TSLNGF19 TSLNGF21 TSLNGF22 TSLNGF24 TSLNGF25 
Zero order R
2
 0.934 0.964 0.978 0.989 0.980 0.962 0.961 
First order R
2
 0.970 0.974 0.971 0.978 0.977 0.978 0.976 
Higuchi R
2
 0.986 0.984 0.987 0.983 0.980 0.982 0.987 
Hixon R
2
 0.830 0.874 0.917 0.841 0.835 0.814 0.696 
Korsmeyer R
2
 0.892 0.871 0.990 0.876 0.892 0.815 0.889 
n 0.857 0.860 0.937 0.851 0.838 0.825 0.862 
Mechanism Non-
Fickian 
Non-
Fickian 
Fickian Non-
Fickian 
Non-
Fickian 
Non-
Fickian 
Non-
Fickian 
 
Ex vivo permeation study:  
The solid lipid nanoparticles enriched in chitosan gels 
exhibited about 3-fold higher permeation of TSLNGF19 
through the excised cornea in comparison to the drug 
suspension after 12 h. The corneal flux of tropicacyl was 
found significantly higher for TSLNGF19 in contrast 
with the drug suspension figure 4. A statistically 
significant drug accumulation in corneal tissue was 
found for TSLNGF19 when compared with tropicacyl. 
These results support the enhanced release of drug from 
the chitosan gels. The increased drug permeation and 
corneal accumulation could be further justified by the 
permeation enhancing properties of oleic acid used as a 
carrier for solid lipid nanoparticles. 
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Figure 4: Ex-vivo corneal permeation of TSLNGF19 formulations (Mean±SD, n=3) statistically significant as 
analyzed by Dunnett comparison test) 
 
In vitro corneal permeation study:  
It presents the results of in vitro corneal permeation 
profile of tropicamide loaded SLN from the chitosan 
gels and commercial eye drop solution (Tropicacyl) 
across the isolated porcine cornea. It can be seen that 
permeation characteristics of tropicamide-loaded 
chitosan gels are comparable to that of conventional 
commercial preparation (Tropicacyl). Furthermore, no 
remarkable difference in values of flux (Jss) and 
apparent permeability (K) was seen as listed in Table 9. 
The preservative was added in the chitosan gels it 
provided % permeation of tropicamide comparable to 
the commercial formulation. This could be attributed to 
the nanometric size of the solid lipid nanoparticles 
enriched in gels. Earlier it was reported that 
nanoparticles provide higher corneal permeation due to 
endocytic uptake. In addition, lipid dioleyltrimethyl 
ammonium propane has also been reported to provide 
corneal penetration enhancing effect.  
 
Table 9: Steady state flux (Jss) and permeability (Kp) of tropicamide through the porcine cornea and corneal 
hydration level. 
Formulation Flux Jss 
( µg/h/cm
2
) 
Apparent permeability coefficient 
Kp ( x 10
3
 cm/h) 
Tropicamide loaded solid lipid nanoparticles 67.32 6.86 
Tropicacyl 72.23 7.15 
 
 
 
Yerikala Ramesh et al                                                                                      Journal of Drug Delivery & Therapeutics. 2018; 8(2):194-207          
ISSN: 2250-1177                                                                              [204]                                                                            CODEN (USA): JDDTAO 
HETCAM assay:  
The HETCAM assay has been considered as one of the 
most sensitive and robust screening tests for the 
prediction of eye irritation properties, especially for 
identifying slightly irritating chemicals. Based on the 
scoring methodology, the irritancy score (IS) of control 
(0.9% NaCl) and TSLNGF19 as observed as 0 (lack of 
coagulation, hemorrhage and lysis during the given time 
limit) that suggested the non-irritating nature of the 
formulations. Unlike, the IS of Irritant (0.1N NaOH) was 
reported 9 as coagulation and hemorrhage occurred 
within the Period of 0.5 min while lysis was observed 
during the 2nd min. (Table 10). Figure 5 exhibited the 
effect of test formulations on HETCAM after the 
specific time limit i.e. 0.5, 2 and 5 min. 
 
 
Figure 5:  HET-CAM assay after treatment with (a) Control, (b) Irritant and (c) TSLNGF19 
 
Table 10: Scoring for irritation testing (HET-CAM assay) 
Test 
Formulation 
Effect Score Net 
score 
 
Inference 0.5 min 2 min 5 min 
Control 
(0.9% Nacl) 
Lysis -- -- -- 0 Non - Irritant 
Haemorrhage -- -- -- 
Coagulation -- -- -- 
Irritant 
(0.1N NaOH) 
Lysis  3  0 Severe irrtant 
Haemorrhage 7 -- -- 
Coagulation 9 -- -- 
TSLNGF19 Lysis -- -- -- 0 Non - Irritant 
Haemorrhage -- -- -- 
Coagulation -- -- -- 
 
Corneal hydration study:  
The percent corneal hydration for the TSLNGF19 
treated cornea was found as 77.21±2.50%, which 
denotes good corneal integrity (Figure 6). For a healthy 
cornea, the hydration level should be in the range 
between 76 and 80%. The irritant (0.1N NaOH) 
exhibited a statistically significant (P = 0.05) value of 
corneal hydration i.e. 85.15 ± 2.15% when compared 
with the control and TSLNGF19. The corneal injury, if 
any, caused by the solid lipid nanoparticles was under 
safe level and could be reversible. Earlier studies 
proposed that the enhancement in hydration level 
(>83%) may cause irreversible damage to corneal 
tissues. In most species, the water content of the normal 
cornea ranges from 3.2 to 4 g/g dry weight, 
corresponding to a 76-80% hydration level. An increase 
in hydration levels up to 83-92% indicates damage of the 
epithelium and/or of endothelium that allows extra water 
to enter the stroma leading to corneal edema. 
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Figure 6: Corneal hydration study for TSLNGF19 (Mean ± SD, n=3) (*P = 0.05; statistically significant as 
analyzed by Dunnett multiple comparison test) 
Histopathology:  
The histopathological images of control and TSLNGF19 
treated cornea exhibited intact epithelial layer without 
any stromal swelling. While the epithelial layer was 
found to be severely damaged at various regions in the 
irritant (0.1N NaOH) treated cornea (Figure 7). In 
addition, highly swelled stroma (corneal edema) was 
observed as result of excessive and uncontrolled fluid 
entry into the stroma through the highly injured 
epithelia.
 
 
Figure 7: Images of histopathology of the isolated cornea after treatment with (a) Control (b) Irritant and (c) 
TSLNGF19 
Stability studies:  
The prepared tropicamide loaded solid lipid 
nanoparticles enriched in chitosan gels were subjected to 
stability study. At the regular intervals, the stored 
samples were evaluated for mean gelling strength, 
Bioadhesive force, viscosity, spreadability coefficient, 
pH. The results were summarized in table 11 to 12.
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Table 11: Mean particle size, zeta potential and drug content estimation of prepared Tropicamide loaded solid 
lipid nanoparticles enriched in chitosan gels subjected to long-term stability as per ICH guidelines (25
°
C ± 2
°
C / 
60% RH ± 5% RH) 
Test duration 
(Months) 
Physical 
change 
Gelling strength 
(sec) 
Bioadhesive 
force* 
(dynes/cm
2
) 
Viscosity* 
(cp) 
Spreadiability 
Coefficient* 
(gm/sec) 
0 No change 148 15.23±1.22 2519±1.15 13.3±1.21 
3 No change 148 15.33±1.36 2519±1.17 13.1±1.25 
6 No change 148 15.57±1.41 2520±1.16 13.6±1.24 
9 No change 149 15.55±1.52 2520±1.24 13.7±1.23 
12 No change 149 15.81±1.27 2521±1.27 13.8±1.25 
The values are expressed as mean ± SD; n=3; 
Table 12: Mean particle size, zeta potential and drug content estimation of prepared Tropicamide loaded solid 
lipid nanoparticles enriched in chitosan gels subjected to accelerated stability as per ICH guidelines (40
°
C ± 2
°
C / 
75% RH ± 5% RH) 
Test duration 
(Months) 
Physical 
change 
Gelling 
strength 
(sec) 
Bioadhesive force* 
(dynes/cm
2
) 
Viscosity* 
(cp) 
SpreadiabilityCoe
fficient* (gm/sec) 
0 No change 148 15.23±1.22 2519±1.15 13.3±1.21 
3 No change 148 15.34±1.40 2513±1.20 13.7±1.26 
6 No change 149  16.06 ± 0.12 2622±0.12 14.1±0.24 
The values are expressed as mean ± SD; n=3; 
CONCLUSION 
The present study concludes that Tropicamide can be 
entrapped in the form of solid lipid nanoparticles using 
chitosan polymer to achieve sustained release action. 
The mucoadhesive property of chitosan and sustain 
release action of solid lipid nanoparticles may contribute 
to enhance corneal residence time of Tropicamide by 
formulating its eye drop.  The SLN enriched in chitosan 
gels pH, spreadability coefficient, bioadhesive force & 
viscosity.  The invitro diffusion release studies carried 
out at 12 hrs TSLNGF19 shows the 79.2 ± 0.32. The ex 
vivo permeation studies for optimized formulation the 
increased drug permeation and corneal accumulation. In 
vitro corneal permeation profile of tropicamide loaded 
SLN from the chitosan gels and commercial eye drop 
solution (Tropicacyl) across the isolated porcine cornea. 
It can be seen that permeation characteristics of 
tropicamide-loaded chitosan gels are comparable to that 
of conventional commercial preparation (Tropicacyl). 
The ocular tolerance studies performed with HETCAM 
assay, corneal hydration study, histopathological studies. 
The stability studies of chitosan gels for long-term 
stability & accelerated stability there is no changes in 
optimized formulation. 
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